Market Signal Briefing

, /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Plug Power Inc. ("Plug Power" or "the Company") (NASDAQ: PLUG) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Investors who purchased the Company's securities between January 17, 2025 and November 13, 2025, inclusive (the "Class Period"), are encouraged to contact the firm before April 3, 2026.

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at [email protected].

The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

According to the Complaint, the Company made false and misleading statements to the market. Plug Power misled investors about the likelihood of it building the hydrogen production facilities necessary to receive DOE Loan funds. The Company was more likely to pivot to smaller projects lacking significant commercial potential. Based on these facts, the Company's public statements were false and materially misleading throughout the class period. When the market learned the truth about Plug Power, investors suffered damages.

Join the case to recover your losses

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

CONTACT:

The Schall Law Firm
Brian Schall, Esq.,
www.schallfirm.com
Office: 310-301-3335
[email protected]

SOURCE The Schall Law Firm

, /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against uniQure N.V. ("uniQure" or "the Company") (NASDAQ: QURE) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Investors who purchased the Company's securities between September 24, 2025, and October 31, 2025, inclusive (the "Class Period"), are encouraged to contact the firm before April 13, 2026.

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at [email protected].

The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

According to the Complaint, the Company made false and misleading statements to the market. UniQure failed to secure full FDA approval for its Pivotal Study. The Company misled the market about the chances it would have to delay its BLA timeline to supplement the data it submitted to the FDA. Based on these facts, the Company's public statements were false and materially misleading throughout the class period. When the market learned the truth about uniQure, investors suffered damages.

Join the case to recover your losses

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.          

CONTACT:

The Schall Law Firm
Brian Schall, Esq.,
www.schallfirm.com
Office: 310-301-3335
[email protected]

SOURCE The Schall Law Firm

SASKATOON, Saskatchewan--(BUSINESS WIRE)--Cameco (TSX: CCO; NYSE: CCJ) has entered a long-term agreement to supply uranium ore concentrate (U3O8) to the Government of India’s Department of Atomic Energy, for use in the country’s fleet of nuclear reactors. The agreement will see Cameco supply nearly 22 million pounds of uranium ore concentrate to India over a nine-year period on market-related price terms, with a total contract value estimated at approximately $2.6 billion.

India currently has 24 operating reactors along with ambitious plans to deploy dozens more to reach 100 GW by 2047. Deliveries under the contract are expected to begin in 2027 and run through 2035 in alignment with Cameco’s long-term contracting strategy. The volumes under this contract were included in the total long-term contracting volumes and in the expected five-year realized uranium price sensitivity analysis, disclosed in the 2025 annual Management’s Discussion and Analysis in February 2026.

Cameco’s CEO Tim Gitzel attended an event in Delhi today to celebrate the agreement alongside Indian Prime Minister Narendra Modi, Canadian Prime Minister Mark Carney and Saskatchewan Premier Scott Moe, highlighting the strong diplomatic and commercial trade relationships between the countries.

“Cameco is proud to be a strategic partner with India to help meet its civil nuclear fuel needs and support its trade relationship with Canada,” said Gitzel. “India is embarking on an ambitious nuclear expansion to power its development plans and meet the future energy security needs of its people. That isn’t possible without a stable supply of uranium fuel. Importantly, this demand underscores an emerging trend of sovereign buyers locking up large volumes from multiple suppliers, and in a window where demand continues to grow and available supplies continue to become more uncertain and constrained. As a proven and reliable producer, Cameco is globally recognized as a nuclear fuel supplier of choice, and we are pleased to be a trusted provider for India once again.”

Cameco previously supplied uranium to India under a five-year contract that began in 2015.

At the time of this news release, the estimated value of the new contract is approximately $2.6 billion based on a uranium price of US$86.95 per pound, which was the average of the month-end UxC and TradeTech uranium spot prices on February 28, 2026, and the exchange rate on February 27, 2026 of USD1.00/CAD1.36. Further details of the newly signed contract are commercially sensitive and confidential.

Forward Looking Information

This news release includes statements and information about expectations for the future, which are referred to as forward-looking information. This forward-looking information is based on current views, which can change significantly, and actual results and events may be significantly different from what is currently expected. Examples of forward-looking information in this news release include: the expected volume of uranium ore concentrate to be supplied, the period over which it is to be supplied and the estimated total contract value; the anticipated beginning and ending dates for deliveries; India’s future plans for deployment of additional reactors and nuclear expansion to meet future energy needs, and the expectation that demand continues to grow and available supplies will continue to become more uncertain and constrained. Material risks that could lead to different results include the risk that delivery obligations under the agreement are not fully satisfied, or are delayed, for unexpected reasons; the risk that prevailing pricing terms at time of delivery do not result in the full amount of the estimated contract value; the risk that India’s future deployment and expansion plans may be impeded or delayed for any reason, and the risk that there is not continued growth in demand. In presenting the forward-looking information, we have made material assumptions which may prove incorrect about our ability to satisfy our delivery obligations fully in a timely manner, future uranium prices and India’s successful implementation of its plans.

About Cameco

Cameco is one of the largest global providers of the uranium fuel needed to power a secure energy future. Our competitive position is based on our controlling ownership of the world’s largest high-grade reserves and low-cost operations, as well as significant investments across the nuclear fuel cycle, including ownership interests in Westinghouse Electric Company and Global Laser Enrichment. Utilities around the world rely on Cameco to provide global nuclear fuel solutions for the generation of safe, reliable, carbon-free nuclear power. Our shares trade on the Toronto and New York stock exchanges. Our head office is in Saskatoon, Saskatchewan, Canada.

As used in this news release, the terms we, us, our, the Company and Cameco mean Cameco Corporation and its subsidiaries unless otherwise indicated.

Coinsilium Group Limited (AQSE:COIN, OTCQB:CINGF, FRA:5CT) has widened its 2026 focus in the digital asset sector, flagging late-stage talks for a potentially material investment in prediction markets infrastructure as it maintains a 182-Bitcoin treasury and looks ahead to Yellow Network’s token launch next week.

In a strategic update, the Aquis-quoted venture builder said its Bitcoin is held through wholly owned subsidiary Forza (Gibraltar) Limited and is intended to underpin balance sheet resilience rather than turn the company into a “pure-play” digital asset treasury vehicle.

The board also reiterated a preference for non-dilutive Bitcoin accumulation, saying equity issuance would only be considered where it is clearly accretive relative to enterprise value.

Coinsilium said it is in the final stages of discussions on a “significant transaction” expected to result in a material equity participation in a venture focused on prediction markets and event-driven finance. Principal terms have been agreed, and due diligence is substantially complete, subject to definitive documentation and customary conditions.

Chief executive Eddy Travia described it as "an important strategic update" that highlights the firm's strategic direction and priorities.

"Over the past year, we have spoken consistently about the strength of our transition - both strategically and financially," he said.

"Today, we are better positioned than at any point in our history. Our balance sheet is robust, underpinned by a strong cash position a well-established treasury, and our portfolio has matured significantly. Importantly, we now have the financial capacity to make meaningful commitments in high-conviction areas where we see genuine structural opportunity, and to support and accelerate these promising blockchain ventures.

Travia added: "We are also pleased to reveal that Coinsilium’s expanded focus for 2026 now includes exposure to the exciting Prediction Markets and Event-Driven Finance space.

"We see this as a rapidly emerging segment of digital market infrastructure, and its potential scale should not be underestimated. In the past, we have demonstrated our ability to identify forward-looking opportunities early, today, we also have the capital strength and operational robustness to act on them with greater impact."

Separately, the company noted Yellow Network has scheduled its token and trading platform launch for 8 March 2026. Coinsilium, which subscribed for a US$200,000 SAFT in April 2022, said it is evaluating options to increase its strategic alignment with Yellow beyond its existing position.

"We believe that Coinsilium is now entering a new phase — defined not only by resilience, but by deliberate expansion and disciplined corporate resource deployment and execution," Travia said. "Notwithstanding current market conditions, this is an exciting period for the company."

XRP Faces $650 Million Selling Pressure as Geopolitical Tensions Escalate Prefer us on Google

472 million XRP worth $652M moved to Binance over the past week.Geopolitical tensions between US, Israel and Iran spark market sell-off.XRP dropped over 4% in 24 hours as geopolitical risk drives defensive positioning.XRP (XRP) holders appear to be adopting a defensive stance amid intensifying geopolitical tensions between the United States, Israel, and Iran.

On-chain data shows more than $650 million worth of XRP flowing into Binance over the past week. The sharp rise in exchange inflows suggests investors may be positioning for increased volatility, raising the risk of short-term downside if market uncertainty persists.

Rising Middle East Tensions Trigger XRP Positioning ShiftBeInCrypto reported that a joint strike by Israel and the United States on Iran on Saturday triggered a sharp sell-off across crypto markets.

“The first strikes were launched shortly after the close of traditional financial markets. This timing amplified uncertainty across risk assets, with crypto reacting almost immediately to the geopolitical shock,” analyst Darkfost stated.

Tensions escalated further over the weekend following reports that Iran’s Supreme Leader, Ayatollah Ali Khamenei, had been killed. Iran has intensified retaliatory attacks targeting Israel and several Gulf Arab countries, deepening fears of broader regional instability. The rising geopolitical risk has weighed heavily on investor sentiment.

Crypto markets have declined alongside other risk assets. Meanwhile, gold surged as capital rotated toward traditional safe havens. XRP has not been immune.

On-chain analyst Darkfost noted that more than 472 million XRP, worth approximately $650 million, were transferred to Binance over the past week. According to the analyst, this was the “largest inflow period of the month of February.”

Follow us on X to get the latest news as it happens

XRP Inflows To Binance. Source: X/DarkfostLarge exchange inflows are often interpreted as a sign of potential selling pressure, as tokens typically need to be moved onto trading platforms before they can be sold. However, inflows do not automatically translate into immediate sell-offs.

Such transfers may also reflect liquidity repositioning, arbitrage strategies, collateral management, or precautionary moves during periods of heightened volatility. Still, it raises concerns.

“Such inflows typically reflect a more defensive posture from investors holding XRP. When large amounts of tokens move onto exchanges, it often signals a potential willingness to sell or at least to position liquidity closer to the market. When amount of flows like this are recorded, they can create the conditions for a sudden wave of selling pressure capable of impacting price action in the short term,” Darkfost said.

The main question is whether the large inflow signals a lasting distribution phase or just a temporary response to crises. Notably, the transfer has caused Binance’s XRP reserves to tick up.

CryptoQuant data showed that exchange reserves had been broadly declining since October 2025. The recent inflow marks a modest reversal of that trend for now.

XRP Exchange Reserve. Source: CryptoQuantMeanwhile, XRP extended its losses in line with the broader crypto market downturn. According to BeInCrypto Markets data, the altcoin has dropped more than 4% in the past 24 hours. At the time of writing, XRP was trading at $1.37.

XRP Price Performance. Source: BeInCrypto MarketsThe next few days will reveal whether this $652 million move was a one-off or signals the start of further adjustments among XRP holders. As geopolitical risk and crypto market structure collide, both near-term volatility and long-term adoption narratives remain at the forefront.

Subscribe to our YouTube channel to watch leaders and journalists provide expert insights

Disclaimer

In adherence to the Trust Project guidelines, BeInCrypto is committed to unbiased, transparent reporting. This news article aims to provide accurate, timely information. However, readers are advised to verify facts independently and consult with a professional before making any decisions based on this content. Please note that our Terms and Conditions, Privacy Policy, and Disclaimers have been updated.

Across Europe, moves were mixed rather than one-way.Switzerland’s SMI was higher by 100.57 points, up 0.72% at 14,014.3, while Greece’s HEX added 101.4 points, up 0.78% at 13,118.38.

Spain’s IBEX 35 fell 135.8 points, down 0.73% to 18,360.8, and Germany’s DAX was almost flat, down 4.76 points, or 0.02%, at 25,284.26.In the UK, the FTSE 100 gained 63.85 points, up 0.59% to 10,910.55.

Several benchmarks were unchanged, including the Netherlands’ AEX at 1,027.02, Belgium’s BEL 20 at 5,443.76, France’s CAC 40 at 8,580.75, and Portugal’s PSI20 at 9,276.09.

Sweden’s OMXS30 rose 17.476 points, up 0.55% to 3,222.753, while Italy’s FTSE MIB fell 216.05 points, down 0.46% to 47,209.89. The broader STOXX 600 edged up 0.67 points, up 0.11% to 633.85, and Denmark’s OMXC 25 added 2.44 points, up 0.14% to 1,731.15.

In currencies, the Swiss franc strengthened against the dollar, with USD/CHF at 0.768, down 0.13%.The euro slipped against the dollar too, with EUR/USD at 1.179, down 0.161%, while GBP/USD traded at 1.345, down 0.23%.

Against sterling, EUR/GBP was slightly higher at 0.877, up 0.08%. The euro was also a touch lower versus the franc, with EUR/CHF at 0.905, down 0.297%, and a bit softer against the yen, with EUR/JPY at 184.19, down 0.081%.

In European rates, the UK 10-year yield rose to 4.307, up 0.14%, while the 10-year Bund was listed at 2.644. Italy’s 10-year was at 3.275 and France’s 10-year was at 3.222.

Across Asia, the tone was mostly risk-off.Hong Kong’s Hang Seng dropped 546.64 points, down 2.05% to 26,083.9.Japan’s Nikkei fell 899.51 points, down 1.53% to 57,950.76, and South Korea’s KOSPI lost 63.14 points, down 1% to 6,244.13.

Singapore’s STI fell 92.35 points, down 1.85% to 4,902.72, while Thailand’s SETI dropped 33.45 points, down 2.19% to 1,494.81. The SGX-CNBC China Growth index slipped 26.541 points, down 1.5% to 1,744.332. Mainland China was steadier, with Shanghai down 0.13% at 4,157.346, while Shenzhen fell 0.94% to 14,359.286.

Australia’s ASX 200 eased 33 points, down 0.36% to 9,165.6, New Zealand’s NZX 50 fell 100.89 points, down 0.74% to 13,622.08, Malaysia’s benchmark dropped 16.96 points, down 0.99% to 1,699.65, and Taiwan’s market slid 169.57 points, down 0.48% to 35,244.92. India’s Nifty 50 was unchanged at 25,178.65.

In Asia FX, the U.S. dollar was a bit stronger against several currencies. USD/JPY was 156.2, up 0.11%, USD/CNY was 6.868, up 0.15%, USD/SGD was 1.266, up 0.142%, and USD/INR was 91.3, up 0.279%.

AUD/USD was flat at 0.711, NZD/USD was 0.599, down 0.083%, and USD/HKD was unchanged at 7.823. The euro against the yen was 184.22, down 0.065%.

Journalist

Posted: March 2, 2026

Ethena’s ENA token gained nearly 10% over the past 24 hours as buyers stepped in near key support. The move followed renewed positioning amid broader market uncertainty.

Daily data showed ENA traded around $0.1036 on the 1st of March, after bouncing from sub-$0.10 lows. That recovery drew fresh derivatives participation.

That shift set up a closer look at positioning metrics.

ENA’s Open Interest climbs Ethena’s [ENA] Aggregated Open Interest rose to approximately $110.5 million, according to Coinalyze data. The chart showed a modest uptick alongside price stabilization.

Rising Open Interest during a rebound typically indicated fresh capital entering positions. In this case, the increase remained controlled rather than explosive.

Even so, the structure suggested traders reopened exposure near local support.

That left attention on order flow behavior.

Source: Coinalyze

Whale activity resurfaces CryptoQuant’s Spot Average Order Size data showed periodic spikes in larger orders. Big whale orders appeared during recent price dips.

Such behavior often reflected accumulation during weakness. Larger participants typically stepped in before broader momentum shifted.

However, the broader trend in whale order size remained uneven. Sustained expansion would be needed to confirm a strong conviction.

That history kept sentiment cautious.

Source: CryptoQuant

Ethena: Structure builds above $0.10 TradingView data showed ENA repeatedly defending the $0.10 zone. The level marked three recent reaction lows.

Price traded near $0.103–$0.104 at the time of writing. Holding above $0.10 kept short-term structure intact.

Source: TradingView

By contrast, overhead liquidity appeared concentrated near the $0.13 region. That area aligned with prior breakdown levels.

A break above $0.13 could shift near-term momentum. Failure to hold $0.10 may reopen downside risk.

ENA’s rebound coincided with steady Open Interest and visible whale participation. That combination suggested positioning rather than panic covering.

However, continuation depended on sustained Spot Volume and broader market stability.

For now, ENA held above key support. Whether bulls could reclaim higher liquidity zones remained the central question.

Final Summary ENA gained nearly 10% in 24 hours, rebounding from repeated defenses of the $0.10 support zone. Ethena’s Aggregated Open Interest rose to around $110.5 million, indicating renewed derivatives participation.

Trusted Editorial content, reviewed by leading industry experts and seasoned editors. Ad Disclosure

Despite maintaining its position as the leading meme coin in the market, Dogecoin has suffered immensely in the market decline. It failed to reach a new all-time high in the 2024-2025 market run-up and has crashed tremendously as selling ramped up. Even now, the bleed seems not to have stopped, with crypto analyst MyCryptoParadise warning investors that the recent recovery could be a crash.

Why The Dogecoin Pullback Could Be Temporary The analysis focuses on Dogecoin’s recovery and its failure to break above any important levels. Instead, the crypto analyst explains that the meme coin is actually still respecting the descending resistance trendline. This failure to break shows that DOGE is still experiencing significant structural weakness.

Another important thing to note is that the price is still holding inside the 1-Hour supply zone, as well as the order block and Fair Value Gap (FVG) zone. This means that the likelihood of the Dogecoin price moving downward is still higher than the possibility of a sustained recovery.

This also spreads into the volume spread, where there has been a plateau in buying action. This trend, the crypto analyst points out, shows that there is distribution happening for DOGE. Thus, it seems the big players are using these spikes to actually sell their holdings. This means that the recovery is unlikely to last long as the price just pumps into more dumping.

Source: TradingView Mapping Out The DOGE Price Weakness In addition to the points above, MyCryptoParadise also outlines a key weakness confirmation that has popped up on the Dogecoin chart. This was the fact that the meme coin was still under the upper trigger line of the buying climax. In a case like this, it points to supply being way too strong that demand cannot absorb it completely.

If this weakness continues, then the recovery could be stopped dead in its tracks. The first support of the downward move would be at $0.09, where buyers would have a chance to make their stance. However, a break below this level would trigger a move toward $0.08030.

Nevertheless, there is still a chance that the bulls could take over, and the analyst says that this can only happen if the Dogecoin price can break above the resistance at $0.10875. To completely invalidate the bearish scenario, this break would have to be done with strong momentum, and that would trigger a bullish continuation.

DOGE continues to push upward | Source: DOGEUSD on Tradingview.com Featured image from Dall.E, chart from TradingView.com

Editorial Process for bitcoinist is centered on delivering thoroughly researched, accurate, and unbiased content. We uphold strict sourcing standards, and each page undergoes diligent review by our team of top technology experts and seasoned editors. This process ensures the integrity, relevance, and value of our content for our readers.

Sign Up for Our Newsletter! For updates and exclusive offers enter your email.

Scott Matherson is a leading crypto writer at Bitcoinist, who possesses a sharp analytical mind and a deep understanding of the digital currency landscape. Scott has earned a reputation for delivering thought-provoking and well-researched articles that resonate with both newcomers and seasoned crypto enthusiasts. Outside of his writing, Scott is passionate about promoting crypto literacy and often works to educate the public on the potential of blockchain.

Bitcoin could benefit if artificial intelligence disrupts labor markets or creates volatility that prompts central banks to ease monetary policy, according to Greg Cipolaro, research lead at crypto services firm NYDIG.

Cipolaro said in a research note on Friday that AI may prove to be a “general-purpose technology” such as electricity, and the macroeconomic effects it would have on employment, economic growth and risk appetite will affect Bitcoin (BTC).

“If AI-driven growth occurs alongside expanding liquidity and contained real rates, that backdrop can be supportive for Bitcoin,” Cipolaro said. “But if stronger growth lifts real yields, tightens policy, and reduces the need for monetary accommodation, Bitcoin may face headwinds.”

“Conversely, if AI generates labor disruption or volatility that prompts fiscal expansion and easier monetary policy, the resulting liquidity impulse would likely favor Bitcoin,” he added.

The economy is already seeing the impact of the technology, as companies have cited AI adoption as part of broader restructuring efforts

Jack Dorsey said on Friday that his payments company Block would cut roughly 40% of its staff due to AI, and predicted that many more companies would soon follow suit.

AI transition may be volatile and unevenGoldman Sachs’ research arm claimed in a report in August that widespread AI adoption could displace up to 7% of the US workforce, but would also likely create new job opportunities.

Cipolaro acknowledged the transition will “pose challenges,” requiring workflow redesign, new skills, and additional investment. Still, he predicts AI will follow the same “historical pattern” as previous technological advancements.

“The implication is not that disruption will be painless, but that the equilibrium response to new technology has historically been integration, not obsolescence. Society's response to AI will likely follow the same pattern,” he said.

“Firms that integrate it effectively will widen margins and productivity gaps. Workers who adapt will enhance their relevance. Those who resist may fall behind,” Cipolaro added.

AI adoption is also expanding within the crypto industry. In October, crypto exchange Coinbase announced a new tool, Payments MCP, that grants AI agents access to the same on-chain financial tools used by people, with AI and blockchain executives noting that it can be safe but also introduces new risks.

Magazine: Bitcoin’s ‘biggest bull catalyst’ would be Saylor’s liquidation — Santiment founder

Cointelegraph is committed to independent, transparent journalism. This news article is produced in accordance with Cointelegraph’s Editorial Policy and aims to provide accurate and timely information. Readers are encouraged to verify information independently. Read our Editorial Policy https://cointelegraph.com/editorial-policy

Bitcoin hasn't traditionally been a great asset to hold during a market crash. Silver is vulnerable to fluctuations in demand owing to its industrial uses.

James Ding Mar 02, 2026 07:37

Bitcoin trades at $65,932 with bearish momentum signals pointing to potential $63,800 test before bullish reversal toward $72,000 resistance zone.

Bitcoin continues its volatile journey as institutional forecasts paint an increasingly bullish long-term picture while short-term technicals suggest consolidation ahead. With BTC trading at $65,932 following a 1.91% decline in the past 24 hours, the cryptocurrency finds itself at a critical juncture between major institutional backing and technical resistance.

BTC Price Prediction Summary • Short-term target (1 week): $63,800-$67,200 consolidation range • Medium-term forecast (1 month): $68,400-$72,000 range
• Bullish breakout level: $68,421 • Critical support: $63,812

What Crypto Analysts Are Saying About Bitcoin While specific analyst predictions from crypto Twitter remain limited in recent hours, major institutional players have issued significant Bitcoin forecasts that shape market sentiment.

VanEck delivered perhaps the most ambitious long-term Bitcoin forecast on January 8, 2026, predicting Bitcoin could reach $2.9 million by 2050 with a 15% compound annual growth rate. This ultra-bullish projection reflects growing institutional confidence in Bitcoin's role as a digital store of value.

However, near-term institutional sentiment has shown some moderation. Standard Chartered revised its Bitcoin forecast downward to $150,000 for 2026 from a previous $300,000 target on January 5, citing concerns about Bitcoin Digital Asset Treasury (DAT) companies' ability to continue aggressive accumulation patterns.

Bernstein maintains a more measured approach with a Bitcoin price target of $150,000 for 2026, alongside a separate projection for a possible peak around $200,000 in 2027. Meanwhile, Bit Mining's chief economist Youwei Yang presents the widest forecast range: $75,000 to $225,000, reflecting the extraordinary uncertainty surrounding multiple competing market forces.

According to on-chain data from major analytics platforms, Bitcoin's fundamentals remain robust despite short-term price volatility, with network hash rate and institutional accumulation patterns supporting longer-term bullish thesis.

BTC Technical Analysis Breakdown Bitcoin's current technical setup presents a mixed but increasingly bearish near-term picture. Trading at $65,932, BTC sits below all major moving averages except the 7-day SMA at $66,299.

The RSI at 39.71 indicates neutral territory but trending toward oversold conditions, suggesting potential buying opportunity emergence. However, the MACD histogram at 0.0000 confirms bearish momentum, with the MACD line at -2,711 signaling continued downward pressure.

Bollinger Bands analysis shows Bitcoin positioned at 0.29 between the bands, closer to the lower band at $64,306 than the upper band at $70,005. This positioning typically indicates oversold conditions developing, though momentum remains negative.

The daily ATR of $2,759 reflects moderate volatility, providing clear trading ranges for position management. Key resistance emerges at $67,177 (immediate) and $68,421 (strong), while support levels sit at $64,872 (immediate) and $63,812 (strong).

Bitcoin Price Targets: Bull vs Bear Case Bullish Scenario The bullish case for this Bitcoin forecast centers on a break above $68,421 resistance, which would target the $72,000-$75,000 zone within 3-4 weeks. Technical confirmation would require:

RSI recovery above 50 MACD histogram turning positive Daily close above the 20-day SMA at $67,156 Volume expansion above the current $1.45 billion daily average A successful bullish breakout could see BTC testing the psychological $75,000 level, aligning with the lower end of institutional forecasts.

Bearish Scenario The bearish scenario suggests further consolidation with potential downside toward $63,812 support. Risk factors include:

Continued MACD bearish divergence Break below $64,872 immediate support Volume declining below $1 billion daily RSI falling toward 30 oversold territory A breakdown below $63,812 could trigger deeper correction toward $58,000-$60,000, though institutional buying interest likely provides strong support in this zone.

Should You Buy BTC? Entry Strategy Based on current technical levels, a layered entry approach appears optimal:

Primary entry zone: $64,000-$65,500 for long-term positions, representing current support confluence and attractive risk-reward ratios.

Aggressive entry: $63,800-$64,200 on any breakdown test, with tight stop-loss at $63,200.

Conservative entry: Wait for bullish confirmation above $67,200 with stop-loss at $65,500.

Position sizing: Given current volatility, limit initial positions to 2-3% of portfolio with ability to add on confirmed breakouts or successful support tests.

Conclusion This BTC price prediction suggests Bitcoin remains in a consolidation phase with medium-term upside potential toward $72,000 despite near-term bearish momentum. The confluence of institutional long-term bullishness and technical oversold conditions creates an attractive setup for patient investors.

However, immediate downside risk toward $63,812 support remains elevated given current MACD bearish signals. The Bitcoin forecast favors buyers on any successful support test, with 65% confidence in reaching $68,400-$72,000 targets within 30 days.

Disclaimer: Cryptocurrency investments carry significant risk. This analysis is for educational purposes and should not constitute financial advice. Always conduct your own research and consider your risk tolerance before making investment decisions.

Image source: Shutterstock

btc price analysis btc price prediction

Bitcoin (BTC) and other major cryptocurrencies edged lower but remained relatively steady on Monday morning in Asia as traders digested a sharp geopolitical shock from the Middle East, while Asian equities fell and oil prices surged after U.S.-Iran war escalated over the weekend.

Bitcoin slipped about 1% over the past 24 hours to trade at $66,772 as of 12:40 a.m. ET Monday, while ether fell 2.2% to $1,971, according to The Block's price page. 

The moves followed weekend volatility linked to escalating U.S.-Iran tensions, including reports that Ayatollah Ali Khamenei, Iran's supreme leader, was killed in a joint U.S.-Israeli airstrike. Bitcoin traded in a choppy range of roughly $63,000 to $66,000 over the weekend.

Analysts, however, said crypto's moves were modest compared with traditional markets and past risk-off episodes.

"Over the weekend, crypto sold off on US‑Israel strikes in Iran, with BTC and ETH dipping toward short‑term support as risk assets were unwound," said Dominick John, an analyst of Kronos Research. "Prices quickly bounced back as traders digested evolving developments, highlighting crypto's 24/7 liquidity and resilience while traditional markets were closed and unable to respond."

Meanwhile, Gulf states have warned they could retaliate against Iran following strikes on key sites that killed at least five civilians, AP News reported. U.S. President Donald Trump also vowed that Washington would "avenge" the deaths of American troops in the region, according to his Sunday post on Truth Social.

Crypto markets effectively served as the first venue for investors to de-risk over the weekend, given their continuous trading hours, analysts said. Jeff Ko, chief analyst at CoinEx, noted that bitcoin held near the $66,000 level despite a sharper sell-off in Asian equities at Monday's open, suggesting the market was treating the geopolitical shock as a temporary risk premium rather than the start of a sustained downturn.

Asian equities fall, oil climbs Traditional markets reacted more sharply when they reopened. 

Japan's Nikkei 225 at one stage fell more than 2.5% around noon, while the broader Topix dropped nearly 3%. Hong Kong's Hang Seng and Singapore's Straits Times Index each fell almost 2%, and Taiwan's Taiex slipped roughly 0.9%. South Korean markets were closed for a public holiday.

Oil prices jumped in early Asian trading, with Brent crude stood at around $78 per barrel at the time of writing, a gain of more than 7% over the past day. Meanwhile, gold rose 1.9% to $5,381 an ounce.

Analysts noted that oil remains the main transmission channel from geopolitical shocks into crypto and other risk assets. 

"If crude pushes and holds above $90, inflation expectations rise, real yields firm and the USD strengthens. This tightens liquidity, and it can be expected that crypto trades like a high-beta macro asset in that regime," said Rick Maeda, research associate at Presto Research.

Jeff Mei, COO of crypto exchange BTSE, said markets are particularly sensitive to any threat to shipping through the Strait of Hormuz, a critical chokepoint for roughly one-fifth of global oil flows. At least three ships were attacked near the Strait of Hormuz, BBC reported. Fears of disruption there have already lifted shipping insurance costs and rerouted vessels, amplifying inflation concerns that could affect central bank rate cut decisions, said Mei.

Resilience Despite the geopolitical shock, on-chain and derivatives indicators showed relatively little systemic stress in crypto markets. Maeda of Presto noted there was no visible stablecoin stress or major liquidation cascades.

Maeda pointed to Hyperliquid, a perpetual futures exchange, where oil-linked and metals contracts moved sharply, enabling continuous price discovery through the weekend turmoil. "Its possible that this round-the-clock derivatives market helped absorb the macro shock in real time," he said.

For now, analysts said crypto appears to be trading with macro risk sentiment but has remained relatively steady compared with traditional assets. The trajectory would hinge largely on the similar variables facing global equities: oil, inflation expectations and the path of the U.S.-Iran conflict.

John of Kronos said traders are closely monitoring oil markets, inflation data, risk-sentiment ETF flows, and any signs of de-escalation. "Crypto's performance will likely track broader macro developments, with volatility remaining elevated until a clearer path forward emerges," he said.

"Traders are focused on whether this stays a headline-driven spike or turns into a sustained tightening of financial conditions," Maeda said. "In regards to asset prices, this means watching oil first, and whether it stabilizes or pushes into a structurally higher range. In parallel, they are tracking U.S. real yields and the dollar for signs that the shock is feeding into broader macro repricing."

Disclaimer: The Block is an independent media outlet that delivers news, research, and data. As of November 2023, Foresight Ventures is a majority investor of The Block. Foresight Ventures invests in other companies in the crypto space. Crypto exchange Bitget is an anchor LP for Foresight Ventures. The Block continues to operate independently to deliver objective, impactful, and timely information about the crypto industry. Here are our current financial disclosures.

© 2026 The Block. All Rights Reserved. This article is provided for informational purposes only. It is not offered or intended to be used as legal, tax, investment, financial, or other advice.

Amid broader market headwinds and persistent volatility across crypto, bold bullish calls are becoming rare. But one high-profile analyst is leaning the other way. Arthur Hayes has sparked fresh rally talk around Hyperliquid (HYPE) suggesting that HYPE price could surge toward $150, nearly a 5x move from current levels. At a time when risk appetite remains fragile, such a projection has quickly reignited debate across the derivatives and on-chain community.

Is this optimism premature, or is Hyperliquid quietly setting up for its next breakout? Let’s take a closer look.

Arthur Hayes’ Bullish Narrative on HYPEHayes believes HYPE price remains in “price discovery,” implying that the market has not yet established a clear long-term ceiling. According to his thesis, the protocol’s rapid growth in perpetual trading volume and ecosystem traction could justify a significantly higher valuation.

🚨 BREAKING

ARTHUR HAYES SAYS $HYPE TO $150

Arthur Hayes believes Hyperliquid’s $HYPE could surge from ~$30 to $150 — nearly a 5x move — as he says the token is still in “price discovery.”

However, on-chain data shows he has reduced part of his position earlier.👀

What’s… pic.twitter.com/hOYhJDjU8Y

— Whale Degen (@hiwhaledegen) March 2, 2026 His $150 projection would represent a substantial expansion from current levels near $31–$32, positioning HYPE among the strongest-performing exchange-native tokens if realized.

However, on-chain observers have noted that Hayes previously reduced part of his exposure, adding nuance to the narrative. While his macro thesis remains bullish, positioning adjustments suggest tactical risk management rather than blind conviction. Still, the call has injected fresh momentum into market sentiment.

HYPE Price Analysis: Falling Wedge Breakout in PlayHYPE token appears to be emerging from a prolonged corrective structure. HYPE’s daily chart shows:

A multi-month falling wedge pattern, typically considered a bullish reversal structure.Price recently broke above the upper wedge resistance.HYPE is now attempting to reclaim the 200-day EMA, currently near the $32 zone.A sustained close above the 200-day EMA would confirm structural strength and potentially trigger momentum inflows. The next key resistance zone sits around $40–$42, followed by a broader supply area near $50.

Notably, the chart projection suggests a possible move toward $50 in the medium term, aligning with the initial breakout measured move. If that level clears decisively, price expansion could accelerate. On the downside, key support rests near:

$29–$30 (breakout retest zone)$25 (major structural support)As long as HYPE holds above wedge support, bulls retain control.

Futures Market Outlook: Hyperliquid’s Positioning Remains ConstructiveBeyond price action, derivatives data offers additional insight. Recent metrics show:

Long/Short Trader Ratio: 1.65Long Traders: 30,369Short Traders: 18,610Funding dynamics indicate elevated short-side pressure relative to longs.

A long/short ratio above 1 signals that more traders are positioned long than short, suggesting constructive sentiment. However, the presence of significant short-side funding implies potential for a short squeeze scenario if price momentum accelerates. If HYPE decisively clears the 200-day EMA and pushes toward $40, forced short covering could amplify upside volatility. This aligns with the technical breakout narrative.

Final WordsWhile the broader crypto market remains cautious, Hyperliquid is showing early signs of structural recovery. Arthur Hayes’ $150 target may appear ambitious, but the technical setup and futures positioning indicate that HYPE is not structurally weak. The first real confirmation comes above $32. The next acceleration likely unfolds above $40, and if $50 clears with conviction, the narrative shifts decisively bullish.

Trust with CoinPedia:CoinPedia has been delivering accurate and timely cryptocurrency and blockchain updates since 2017. All content is created by our expert panel of analysts and journalists, following strict Editorial Guidelines based on E-E-A-T (Experience, Expertise, Authoritativeness, Trustworthiness). Every article is fact-checked against reputable sources to ensure accuracy, transparency, and reliability. Our review policy guarantees unbiased evaluations when recommending exchanges, platforms, or tools. We strive to provide timely updates about everything crypto & blockchain, right from startups to industry majors.

Investment Disclaimer:All opinions and insights shared represent the author's own views on current market conditions. Please do your own research before making investment decisions. Neither the writer nor the publication assumes responsibility for your financial choices.

Sponsored and Advertisements:Sponsored content and affiliate links may appear on our site. Advertisements are marked clearly, and our editorial content remains entirely independent from our ad partners.

Bitcoin Price Prediction: What To Expect From BTC In March 2026 Prefer us on Google

Bitcoin’s bear flag risks a 39% drop, but sell pressure is fading fast across the board.Whale accumulation and collapsing ETF outflows hint at a local bounce before further pain.March hinges on $62,300 support vs $79,000 resistance — one breaks first, direction follows.​​​​​​​​​​​​​​​​The Bitcoin price enters March bruised. February delivered close to 15% losses, echoing last year’s February, which saw the Bitcoin price drop by over 17%.

With five consecutive red months now on the books, starting from October 2025, and a median March return of −1.31%, the seasonal backdrop offers little comfort. But beneath the surface, a shift may be forming. Here is what the data shows heading into March.

Bitcoin Price Still Trades as a Risk AssetOne of the most pressing concerns for the Bitcoin price right now is its sustained correlation with US equities. This reflects in the historical sightings as a weak S&P 500 month-on-month ensured a dismal February for Bitcoin.

Want more token insights like this? Sign up for Editor Harsh Notariya’s Daily Crypto Newsletter here.

BTC Price History: CryptoRankAs of March 1, the 30-day rolling correlation between Bitcoin and the S&P 500 stands at 0.55, up from around 0.50 in October 2025.

Bitcoin vs US Equities Correlation: NewhedgeThis means the Bitcoin price continues to move largely in step with stocks, undermining its appeal as a hedge against traditional market risk. With Trump’s new global tariffs adding pressure to equities and potential US-Iran military escalation weighing on risk appetite, Bitcoin’s risk-on behavior keeps it vulnerable.

Kevin Crowther, Founder of KC Private Wealth, emphasized this dynamic.

“Bitcoin’s high correlation to software stocks weakens its case as a hedge asset in times of uncertainty, and so as Trump continues to elevate economic uncertainty, continued BTC weakness should be expected,” Crowther said.

Meanwhile, gold and silver continue to surge while Bitcoin bleeds. However, if geopolitical tensions ease, particularly around Iran, risk sentiment could shift. And if the gold and silver trade becomes saturated, capital could begin rotating into Bitcoin as the next uncrowded allocation. That rotation hinges on the equity correlation breaking.

Bitcoin ETF Outflows Are Fading: A Quiet ShiftWhile the macro picture remains challenging, spot Bitcoin ETF data tells a more nuanced story. February marked the fourth consecutive month of net outflows, but the trend is shifting sharply.

Historical ETF Data: SoSoValueNovember 2025 saw $3.48 billion in outflows. December brought $1.09 billion, January $1.61 billion, and February closed at just $206.52 million — a 94% reduction from November’s peak.

Orkun Mahir Kılıç, Co-Founder of Citrea, noted that these outflows reflect positioning adjustments rather than a structural retreat.

“The ETF outflows are more consistent with deleveraging than institutional abandonment. For flows to reverse meaningfully, markets need clearer macro direction and lower volatility,” Kılıç explained in an exclusive quote to BeInCrypto.

Nima Beni, Founder of Bitlease, was more direct about what the data signals, especially taking BlackRock’s IBIT outflow into account:

“ETF outflows are retail panic, creating institutional opportunity. BlackRock’s $2.13B IBIT outflow matters less than the fact that 94% of ETF Bitcoin holdings remained despite maximum fear. That’s institutional conviction, not abandonment,” Beni stated.

Overall, the experts didn’t seem perturbed by the ETF outflow streak.

Selling Pressure Is Exhausting Across the Board – The Bounce Catalyst?Beyond ETFs, on-chain data shows that selling from both long-term holders and Bitcoin miners is drying up rapidly.

Long-term holders — wallets that have held Bitcoin for 365 days or more — are a critical group for gauging market direction. When their selling ends, the Bitcoin price tends to stabilize and recover. Throughout February, their net selling has collapsed. On February 5, the 30-day rolling net position change for long-term holders stood at −243,737 BTC. By March 1, that figure had fallen to just −31,967 BTC, an 87% reduction.

Long-Term Holder Net Position Change: GlassnodeMiner behavior mirrors this trend. Bitcoin miners, who sell BTC to cover operational costs, saw peak capitulation around February 8 when net selling hit −4,718 BTC. By March 1, that had eased to −837 BTC, a sharp decline that suggests the worst of miner capitulation may be behind us.

Miner Net Position Change: GlassnodeHan Tan, Chief Market Analyst at Bybit, offered a key distinction here, taking the negative hash rate growth into account.

“Bitcoin miners aren’t capitulating; they’re making strategic diversifications. The drawdown in the hashrate is only to be expected in light of Bitcoin’s price plummet, but does not imply structural capitulation,” Tan noted.

Negative hash rate growth means the total computing power securing Bitcoin is falling instead of rising. This usually happens when miners turn off machines because mining becomes less profitable, often due to lower Bitcoin prices or higher energy costs. This explanation validates what Tan just highlighted.

Whales Are Accumulating Near the 20-Day SMAWhile selling weakens, buying is quietly picking up among whale cohorts. Wallets holding between 100,000 and 1,000,000 BTC increased their holdings from 676,540 to 690,000 BTC around February 19–20, during a brief 4.06% price rebound. Crucially, they have not sold since.

Meanwhile, smaller whales holding between 1,000 and 10,000 BTC began accumulating from February 25, with holdings rising from 4.222 million to 4.23 million BTC.

BTC Whale Holdings: SantimentWhy are whales holding?

One likely reason is the 20-day Simple Moving Average (SMA), a short-term trend indicator that smooths prices over 20 days. The Bitcoin price currently trades just below the 20-day SMA at $67,100. The last time this level was decisively crossed — on January 1 — Bitcoin rallied by over 12%. Whales appear to be positioning for a similar breakout.

Key Price Levels: TradingViewHowever, the long-term picture requires more conviction. The 50-day SMA sits at $77,200, and the 200-day SMA — the level that could genuinely confirm a bullish reversal — is far above at $96,800.

Han Tan from Bybit highlighted the importance of one such level:

“To the upside, Bitcoin may have to resurface above its 50-day SMA and reclaim the psychological $80k handle before more buyers are enticed back into the fold,” he added.​​​​​​​​​​​​​​​​

Bear Flag Threatens Bitcoin Price, but Invalidation Is in PlayOn the three-day chart, the Bitcoin price trades inside a bear flag, a bearish continuation pattern where price consolidates upward within parallel trendlines after a sharp drop. The flagpole measures a roughly 39% decline, meaning a confirmed breakdown could project a similar move lower.

Adding weight to this, a hidden bearish divergence has formed on the Relative Strength Index (RSI), a momentum oscillator. Between February 6 and February 24, the Bitcoin price printed a lower high while RSI printed a higher high. This mismatch suggests that despite the bounce, underlying momentum still favors the downside.

Bearish Price Structure: TradingViewThe key levels are clear. On the upside, $71,300 is the first significant resistance. A move above $79,000 would invalidate the bear flag. However, continued BTC price bounces can also shift the structure toward a rising channel, which would become bullish. The next few 3-day candles would therefore determine if the flag breaks or the extension invalidates the bearish pole-and-flag rule.

On the downside, a breakdown below $62,300 opens the door to Fibonacci support levels at $56,800, $52,300, $47,800, and, in extreme scenarios, $41,400.

Bitcoin Price Analysis: TradingViewCrowther sees the most probable outcome as relatively contained, highlighting the chance of a mild bounce.

“Flat, or slightly positive price movement throughout March should be an investor’s base case scenario for now,” he said.

Kılıç, however, pushed back on the bearish framing, aligning with the on-chain selling exhaustion and bounce hopes:

“Extreme fear and the deepest ETF outflow streak in a year aren’t bearish signals. I’d actually define them as classic capitulation, flushing out weak hands and tightening supply,” he stated.

The most likely path for March, therefore, involves a local bounce — driven by exhausting sell pressure and whale accumulation — followed by renewed selling as the broader bear flag structure resolves. Selling is weakening, but it hasn’t been extinguished. A local bottom is not the same as a cycle bottom. March will likely be defined by whether $62,300 support holds or $79,000 resistance breaks first.

Disclaimer

In line with the Trust Project guidelines, this price analysis article is for informational purposes only and should not be considered financial or investment advice. BeInCrypto is committed to accurate, unbiased reporting, but market conditions are subject to change without notice. Always conduct your own research and consult with a professional before making any financial decisions. Please note that our Terms and Conditions, Privacy Policy, and Disclaimers have been updated.

TLDR BTC plummeted to approximately $63,000 during the weekend following coordinated U.S.-Israel military operations against Iran, then bounced back toward $67,000 Unconfirmed reports claiming Iran’s Supreme Leader had been assassinated temporarily lifted BTC past $68,000 Oil prices spiked as high as 13%, maintaining downward pressure on risk-sensitive assets like Bitcoin Critical U.S. employment figures due Friday could trigger additional Bitcoin volatility Technical analysis reveals a bearish pennant formation suggesting possible decline to the $52,000 region Bitcoin experienced significant downward pressure throughout the weekend as coordinated military operations by the United States and Israel against Iranian targets sent shockwaves through global financial markets.

Bitcoin (BTC) Price The leading digital asset by market capitalization slid to approximately $63,255 on Saturday, representing a decline of roughly 6.5%, before staging a recovery that brought prices back above the psychologically important $67,000 threshold by Monday.

As Asian markets opened Monday, BTC was changing hands near $66,197, reflecting a 2.1% daily decline.

Feb 2022: Russia attacked Ukraine.

▫️ $BTC dumped first and then rallied 40%.

June 2025: Israel attacked Iran.

▫️ Bitcoin dumped first and then rallied 25%.

Feb 2026: US attacked Iran.

Will a similar pattern follow again? pic.twitter.com/b8FLF4aR9p

— Ted (@TedPillows) February 28, 2026

The military campaign reportedly resulted in the death of Iran’s Supreme Leader Ayatollah Ali Khamenei — unconfirmed reports that momentarily propelled Bitcoin beyond $68,000 before the rally lost momentum.

Tehran retaliated with successive rounds of missile attacks aimed at American and Israeli military facilities. President Trump indicated the military operations would persist for the foreseeable future.

$BTC price action is pretty simple lately.

We're waiting for a resolution of this rectangle.

Break above $71.8k = bullish; relief rally in store.
Break below $62.6k = bearish; $60k or lower in store.

One interesting thing: BTC pumped yesterday on the war news re: Iran.… pic.twitter.com/AQTkznNx0r

— 𝙲𝚘𝚕𝚒𝚗 𝚃𝚊𝚕𝚔𝚜 𝙲𝚛𝚢𝚙𝚝𝚘 🪙 (@ColinTCrypto) March 1, 2026

Ethereum experienced a steeper correction, dropping approximately 10% following the escalation, with prices hovering around $1,950 by Sunday.

Energy Markets and Traditional Safe Havens Rally Crude oil markets demonstrated dramatic volatility in response to the Middle East tensions. Brent crude surged up to 13% while West Texas Intermediate posted gains approaching 10% during Sunday evening trading.

Gold advanced roughly 2%, climbing to its highest levels in several weeks as capital rotated into traditional safe-haven instruments.

Sean Farrell, Fundstrat’s head of digital assets, noted that geopolitical-driven selloffs often present buying opportunities, though he identified crude oil as the critical variable to monitor. He cautioned that any interruption to global shipping routes or energy supply chains could exert additional downward pressure on Bitcoin valuations.

U.S. equity index futures declined during Asian session trading, signaling a challenging opening for Wall Street.

Critical Economic Releases and Technical Outlook Market participants are now focusing attention on a densely packed U.S. economic calendar. Monday brings the ISM Manufacturing index, with ADP employment figures and ISM Services data scheduled for Wednesday.

The week’s centerpiece arrives Friday with the Nonfarm Payrolls release, a report that consistently influences Treasury yields and dollar strength — two factors with documented correlation to Bitcoin price action.

From a technical perspective, BTC appears to be developing what market observers characterize as a bearish pennant pattern following its retreat from the $73,000–$74,000 zone. This formation indicates the cryptocurrency may consolidate within a $63,000 to $69,000 trading corridor near-term.

A decisive break below this range could send prices toward support in the $51,800–$52,000 area, based on pattern-based price projections.

Bitcoin has declined 23% year-to-date and registered losses for five consecutive months. The asset reached an all-time peak of $126,000 in October.

Several institutional analysts are now modeling scenarios where BTC tests the $50,000 level before potentially establishing a base for recovery during the year’s second half.

At the time of writing Monday, BTC was trading around $65,961.

Trusted Editorial content, reviewed by leading industry experts and seasoned editors. Ad Disclosure

Arthur Hayes argues that a deeper US conflict with Iran could ultimately become a bullish macro setup for Bitcoin, not because war is constructive for markets, but because it may push the Federal Reserve toward cheaper and more abundant money.

Why Bitcoin Could Surge In his March 2 essay iOS Warfare, the BitMEX co-founder laid out a simple thesis: if President Donald Trump commits the US to a prolonged and expensive campaign tied to Iran, the political and fiscal strain could raise the odds of monetary easing. For Hayes, that matters more than the conflict itself. “The longer Trump engages in the extremely costly activity of Iranian nation-building,” he wrote, “the higher the likelihood the Fed lowers the price and increases the quantity of money to support Pax Americana’s latest bout of Middle Eastern adventurism.”

Hayes’ argument rests on a historical pattern rather than a direct forecast on oil, geopolitics or battlefield outcomes. He points to prior US military engagements in the Middle East and says major conflicts were followed, or accompanied, by easier monetary policy. In his reading, wars do not just damage confidence and strain public finances; they also create conditions in which the Fed has cover to cut rates, support liquidity and help stabilize asset markets.

To support that view, Hayes cites several episodes going back to 1990. After the Gulf War began, he notes, the Fed initially stayed put but signaled that worsening conditions could force a shift. From the August 21, 1990 FOMC discussion, he quotes: “The heightened uncertainties and the prospectively less satisfactory performance of the economy stemming from events in the Middle East had greatly complicated the formulation of an effective monetary policy. In the opinion of several members, events appeared likely to unfold in a direction that would require an easing of policy at some point to counter weakening tendencies in the economy that had been in train before the oil price increase.”

He also highlights the Fed’s response after the September 2001 attacks and the launch of the Global War on Terror. In an emergency meeting, then-Chair Alan Greenspan said: “It’s clear that the events of last week, at a minimum, have created a heightened degree of fear and uncertainty that is placing considerable downward pressure on asset prices, increasing the probability of an asset price deflation, with its obvious impact on the economy. Therefore, I propose a 50-basis point cut in the federal funds rate target.”

For Hayes, those episodes show that geopolitical shocks can become monetary events. His framing is blunt: when war dents confidence, threatens growth or pressures markets, the policy answer tends to be lower rates and more liquidity. That, in turn, is the backdrop he believes tends to favor Bitcoin.

Still, Hayes is not calling for an immediate risk-on trade. He says the market does not yet know how long Trump would stay committed to reshaping Iran, nor how much market or political pain the administration can absorb before changing course. Because of that, he argues the cleaner trade is to wait for confirmation from policy rather than front-run the thesis too early.

“The prudent action is to wait and see,” Hayes wrote. “The time to back up the truck and buy Bitcoin and high-quality shitcoins like HYPE is immediately after the Fed cuts rates and or prints money to support the government’s goals in Iran.”

At press time, Bitcoin traded at $66,218.

Bitcoin must reclaim the 200-week EMA, 1-week chart | Source: BTCUSDT on TradingView.com Featured image created with DALL.E, chart from TradingView.com

Editorial Process for bitcoinist is centered on delivering thoroughly researched, accurate, and unbiased content. We uphold strict sourcing standards, and each page undergoes diligent review by our team of top technology experts and seasoned editors. This process ensures the integrity, relevance, and value of our content for our readers.

Sign Up for Our Newsletter! For updates and exclusive offers enter your email.

Jake Simmons has been a Bitcoin enthusiast since 2016. Ever since he heard about Bitcoin, he has been studying the topic every day and trying to share his knowledge with others. His goal is to contribute to Bitcoin's financial revolution, which will replace the fiat money system. Besides BTC and crypto, Jake studied Business Informatics at a university. After graduation in 2017, he has been working in the blockchain and crypto sector. You can follow Jake on Twitter at @realJakeSimmons.

TLDR ETH has experienced six consecutive monthly declines, representing its second-longest bearish streak since the 2018 crash. The cryptocurrency is hovering near its 2018 peak price level, currently struggling below the $2,000 mark. Multiple headwinds include large holder distribution, derivative market pressure, Layer 2 network competition, and persistent ETF capital outflows. Ethereum co-founder Vitalik Buterin suggests artificial intelligence could dramatically accelerate the network’s development timeline and strengthen security protocols. Wall Street analysts from Standard Chartered and VanEck maintain bullish long-term projections of $7,500 and $10,000 for ETH. For the first time since the brutal 2018 bear market, Ethereum has registered six consecutive monthly closes in negative territory, establishing a concerning pattern that has traders questioning when the trend will reverse.

Market data from CoinGlass reveals that the only comparable stretch occurred during 2018’s devastating downturn, when ETH plummeted beneath the $85 threshold.

That previous collapse stemmed primarily from the implosion of the Initial Coin Offering (ICO) boom, as countless projects that had raised capital through ERC-20 token sales on Ethereum’s network simultaneously liquidated their holdings.

Today’s prolonged decline, however, stems from an entirely different combination of pressures.

Market observers identify several concurrent factors: systematic distribution by large wallet holders, aggressive selling in derivatives markets, broader economic instability, sustained withdrawals from spot Ethereum ETFs, and intensifying competition from Ethereum’s own Layer 2 scaling solutions that are siphoning away transaction fee revenue.

ETH currently trades marginally above the peak price it achieved during the 2018 cycle, a threshold that was previously celebrated as a significant psychological barrier.

Ethereum (ETH) Price Following a brief climb to $2,054, the asset retreated below the psychologically important $2,000 level. The price now sits beneath the 100-hour Simple Moving Average, a technical indicator often watched by short-term traders.

Critical Price Zones Under Surveillance The nearest resistance barrier stands at $2,000, followed by more substantial obstacles at $2,120 and $2,155.

$ETH is almost back to the $2,000 level.

It has fully recovered from yesterday's dump, which is a good sign.

Now Ethereum needs to reclaim the $2,100 level, and it could rally towards the $2,400 zone. pic.twitter.com/gcM1LmljND

— Ted (@TedPillows) March 1, 2026

Should Ethereum mount a rally past $2,155, traders would then focus on resistance zones at $2,220 and $2,250.

Conversely, downside protection currently exists at $1,920, with another support layer at $1,880. A breach below $1,880 would likely trigger a test of $1,840 or $1,800, while $1,740 represents a more substantial floor should selling intensify.

Buterin Discusses AI’s Potential Impact on Ethereum Development Ethereum founder Vitalik Buterin recently shared his perspective on how artificial intelligence tools could dramatically compress the timeline for implementing Ethereum’s technical roadmap.

This is quite an impressive experiment. Vibe-coding the entire 2030 roadmap within weeks.

Obviously such a thing built in two weeks without even having the EIPs has massive caveats: almost certainly lots of critical bugs, and probably in some cases "stub" versions of a thing… https://t.co/ZlTg0r2hvI

— vitalik.eth (@VitalikButerin) February 28, 2026

His remarks followed a demonstration where a developer utilized AI assistance to prototype Ethereum’s entire vision through 2030 in just a matter of weeks.

Buterin personally experimented with AI coding capabilities, successfully building a version of his personal blog software in approximately one hour using only his laptop.

He proposed that approximately half of the efficiency gains achieved through AI should be redirected toward enhancing security measures, including expanded testing protocols and formal verification processes for code.

“People should be open to the possibility that the Ethereum roadmap will finish much faster than people expect,” Buterin wrote.

He further emphasized that completely bug-free code, once dismissed as an unattainable ideal, might soon become the baseline standard throughout cryptocurrency development.

Financial analysts at Standard Chartered maintain their ambitious long-term projection of $7,500 for ETH, grounded in Ethereum’s dominant position within stablecoins, decentralized finance protocols, and asset tokenization infrastructure.

VanEck has established an even more optimistic target of $10,000, pointing to the forthcoming Pectra and Glamsterdam network upgrades, which could theoretically enable processing of 100,000 transactions per second.

ETH continues to maintain a foothold above the $1,900 support threshold following its most recent decline from the $2,054 local high.

New York, New York--(Newsfile Corp. - March 2, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into GRAIL, Inc. ("GRAIL, Inc.") (NASDAQ: GRAL) concerning potential violations of the federal securities laws.

On the Q3 2025 earnings call on November 12, 2025, CFO Aaron Freidin told investors the Company was "updating our cash-burn guidance further to no more than $290 million for the full year of 2025." In the same remarks, CEO Robert Ragusa stated: "We believe our cash runway extends into 2030, enabling us to achieve major planned clinical and regulatory milestones." Those milestones included completion of the FDA PMA submission and full clinical-utility results from the 140,000-participant NHS Galleri study. The cash-burn figure and runway projection were presented as sufficient to fund a pathway that, following the trial's failure, may require additional studies, revised timelines, or materially different capital needs.

If you suffered a loss on your GRAIL, Inc. securities and would like to explore a potential recovery under the federal securities laws, Learn More About the Investigation or contact Joseph E. Levi, Esq. via email at [email protected] or call (212)363-7500 to speak to our team of experienced shareholder advocates.

WHY LEVI & KORSINSKY: Over the past 20 years, Levi & Korsinsky LLP has established itself as a nationally-recognized securities litigation firm that has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. The firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States. Attorney Advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 27th Floor
New York, NY 10004
[email protected]
Tel: (212)363-7500
Fax: (212)363-7171

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/285892

Source: Levi & Korsinsky, LLP

Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.

Contact Us

By Reuters

March 2, 20265:56 AM UTCUpdated 39 mins ago

Item 1 of 2 A Tesla Model S electric car is displayed on media day at the 2024 Paris Auto Show in Paris, France, October 14, 2024. REUTERS/Benoit Tessier

[1/2]A Tesla Model S electric car is displayed on media day at the 2024 Paris Auto Show in Paris, France, October 14, 2024. REUTERS/Benoit Tessier Purchase Licensing Rights, opens new tab

CompaniesCOPENHAGEN, March 2 (Reuters) - Registrations of new Tesla (TSLA.O), opens new tab cars in Denmark fell 18% in February from a year earlier, to 419 vehicles, data from Mobility Denmark showed on Monday.

The Reuters Inside Track newsletter is your essential guide to the biggest events in global sport. Sign up here.

Reporting by Anna Ringstrom, editing by Stine Jacobsen

Our Standards: The Thomson Reuters Trust Principles., opens new tab

New York, New York--(Newsfile Corp. - March 2, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Alight, Inc. ("Alight, Inc.") (NYSE: ALIT) concerning potential violations of the federal securities laws.

Alight's Q4 2025 results landed below the low end of the Company's own full-year 2025 guidance range. On the Q3 2025 earnings call on November 5, 2025, CFO Jeremy Heaton told investors the Company expected full-year 2025 EPS of $0.54 to $0.58 and revenue between $2.25 billion and $2.28 billion. The Q4 2025 report disclosed results that fell short of those figures, with revenue declining 4% year over year.

The earnings release also coincided with previously undisclosed leadership changes at the CEO and CFO level -- transitions that had not been referenced on either the Q2 or Q3 2025 earnings calls. The Company additionally announced that its quarterly dividend would be replaced. These developments came after CEO David Guilmette stated on November 5, 2025: "We are intensely focused on execution and improving our top-line performance and remain confident in our position for the long term."

If you suffered a loss on your Alight, Inc. securities and would like to explore a potential recovery under the federal securities laws, Learn More About the Investigation or contact Joseph E. Levi, Esq. via email at [email protected] or call (212)363-7500 to speak to our team of experienced shareholder advocates.

WHY LEVI & KORSINSKY: Over the past 20 years, Levi & Korsinsky LLP has established itself as a nationally-recognized securities litigation firm that has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. The firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States. Attorney Advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 27th Floor
New York, NY 10004
[email protected]
Tel: (212)363-7500
Fax: (212)363-7171

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/285895

Source: Levi & Korsinsky, LLP

Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.

Contact Us

-

Keynote speech, executive forums, and roundtables feature strategies for accelerating grid modernization

LOS ALTOS, Calif.--(BUSINESS WIRE)--Bidgely will deliver the keynote address at the upcoming IDC European Utilities Xchange, taking place March 2 - 3 in Valencia, Spain. Through a series of executive roundtables, interactive workshops and fireside chats, Bidgely will demonstrate how European energy retailers and Distribution System Operators (DSOs) can transform raw smart meter data into a definitive layer of unified intelligence for managing the complexities of growing electrification, regulatory mandates, price volatility and customer engagement.

Our goal at IDC Xchange is to demonstrate how AI-based analytics empowers utilities to become trusted advisors.

Share “As European energy leaders accelerate grid modernization, we are moving beyond generic horizontal AI into a new era of verticalized intelligence that transforms the grid into a dynamic engine," said Gautam Aggarwal, Chief Revenue Officer of Bidgely. "Our goal at IDC Xchange is to demonstrate how AI-based analytics empowers utilities to become trusted advisors, bridging the gap between providers and consumers, specifically as the industry embraces dynamic pricing and time-of-use tariffs.”

Bidgely-Led Speaking Sessions

The ‘Energy Advisor’ Pivot: Leading the Age of Volatility & AI
Monday, March 2, 2:35 PM

Bidgely’s VP EMEA & APAC, Nipun Jain, will explore how AI-based analytics helps manage consumer trust and the adoption of time-of-use (TOU) tariffs. By leveraging zero-hardware disaggregation to build personalized energy profiles, he will demonstrate how utilities can navigate the transition from commodity sellers to essential architects of an electrified energy lifestyle.

Aligning on the Future: UtilityAI Pro, Data Fabric and the AI-Powered Utility
Tuesday, March 3, 9:30am

Bidgely’s Chief Product Officer, Ted Nielsen, and IDC’s Head of Energy Insights Europe, Gaia Gallotti will discuss the leap from horizontal AI to UtilityAI Pro—the industry’s first vertical AI platform—that allows CXOs to eliminate technical debt, unlock 10X data granularity and transform the grid from a passive asset into a dynamic, self-optimizing engine.

To learn how Bidgely empowers energy retailers to leverage AI-driven data insights, download the playbook: Behind-the-Meter Intelligence for Clean Energy.

About Bidgely

Bidgely is the pioneer of AI-powered energy intelligence, transforming raw meter data into high-definition insights for global utilities. Serving over 50 million homes, the company’s UtilityAI™ Platform leverages 17 foundational patents to optimize grid visibility, call center operations, and personalized customer engagement. Recognized by Fast Company as a "Top 10 Most Innovative" company, Bidgely integrates precision energy analytics with horizontal AI ecosystems like Microsoft Copilot and AWS to modernize the grid with premises-level accuracy. www.bidgely.com | bidgely.com/blog

More News From Bidgely

Back to Newsroom

BARCELONA, Spain, March 02, 2026 (GLOBE NEWSWIRE) -- Space42, the UAE-based AI-powered SpaceTech company, and Viasat, Inc., a global leader in satellite communications, will discuss continued progress toward their planned direct-to-device (D2D) infrastructure and offer an early look at the priorities for Equatys, the companies' forthcoming joint entity, during a co-hosted program at Mobile World Congress in Barcelona this week. The program marks the first public showcase of Equatys' technical direction and commercial vision, reflecting its ambition to accelerate global D2D adoption.   This event brings together policymakers, regulators, and industry leaders to explore how competition, resilience, and sovereignty can be advanced simultaneously, along with enabling new business cases, turning space-enabled mobility into a shared success story for all.

Space42 and Viasat are the cofounders of Equatys, bringing together over 60 years of combined mobile satellite services experience. Equatys is designed as an independent, neutral, multi-participant shared infrastructure platform to extend 3GPP-based connectivity to the billions underserved by terrestrial networks. Since announcing Equatys in September 2025, the cofounders have advanced the program across initiation of venture formation, engineering development, and initial commercial engagement with Mobile Network Operators (MNOs), marking concrete progress toward phased deployment.

Mark Dankberg, CEO and Chairman of Viasat, said: "Space-enabled mobility is a foundational layer for global, seamless connectivity. With Equatys, we are building a platform that empowers nations, operators, and innovators to extend secure, affordable, 3GPP-aligned satellite connectivity to billions. This scalable global model ensures the full ecosystem of participants can benefit from lower barriers to entry, expanded supplier diversity and economies of scale, and stronger competitive dynamics across the value chain.   We are committed to delivering a frictionless end-user experience with seamless handover enabling choice for the carriers. "

Karim Michel Sabbagh, Managing Director of Space42, said: "Equatys reflects disciplined execution against a clear objective: combining the scale of terrestrial networks with the efficiency of space. The collaboration is rooted in Space42's strategy to become a global leader in Non-Terrestrial Networks, and to date has achieved significant engineering milestones, with subscription agreements underway, mobile network operators engaged, and international filings submitted. Equatys demonstrates how space-enabled mobility can modernize legacy Mobile Satellite Services, augment terrestrial networks in lacking areas, and unlock new services across markets."

Ali Al Hashemi, CEO of Space Services at Space42, commented: "Equatys is being built on the principle that shared infrastructure benefits all. The spectrum access model allows nations to retain their sovereign autonomy and licensee control, while advancing satellite capacity with significant cost savings. Combined with a standards-based architecture designed to allow seamless, automatic transition between terrestrial and satellite networks, we intend to scale space-enabled connectivity to those beyond traditional network reach." 

Constellation Architecture and Spectrum Strategy

The system is expected to operate initially in globally harmonized L- and S-band MSS spectrum, with technical capability to operate across over 100 MHz of globally allocated and coordinated MSS spectrum. By aligning with 3GPP standards, the platform will integrate terrestrial and satellite networks, enabling seamless transition when terrestrial service becomes unavailable. This will be done while preserving operators’ choice within the -Terrestrial Network ecosystem.

Operating on a Tower Co. model, Equatys intends to deliver the lowest unit cost of satellite capacity while preserving each partner's spectrum rights and sovereign interests. The model is designed to welcome additional cofounders, satellite operators, and spectrum holders as the ecosystem takes shape. Efficient payload and ground technologies are intended to minimize mass-to-orbit requirements while supporting long-term scalability and capital efficiency.

Equatys' shared multi-tenant infrastructure will be supported by up to 2,800 satellites across 60 orbital planes and three altitude layers, deployed by Viasat and Space42. The architecture is intended to densify without fundamental redesign, enabling ecosystem growth at a market-responsive pace and catering to billions of potential users as demand scales.

Commercial Momentum

Space42 has announced partnerships to explore Equatys-enabled D2D connectivity with e& UAE, the flagship telecom arm of global technology group e&, and with PT Telkom Satelit Indonesia (Telkomsat), Indonesia's national satellite operator.

These engagements reflect operator interest in extending coverage through integrated satellite-terrestrial architectures, aligned with national regulatory frameworks and 3GPP standards.

The venture remains subject to definitive agreements, regulatory approvals, and customary closing conditions. The companies intend to provide further updates as Equatys progresses toward formal establishment.

Mobile World Congress

As part of the co-hosted MWC program, Viasat CEO and Chairman Mark Dankberg and Space42 Managing Director Karim Sabbagh will conduct a Fireside Chat to discuss the opportunities and policies shaping the future of space-enabled mobility. The program will explore how the next generation of space-enabled connectivity can be designed to preserve competition, unlock new service capabilities, and align with sovereign priorities, while strengthening resilience and expanding choice.

Attendees can register for the Fireside Chat and other co-hosted panels [here].

About Space42

Space42 (ADX: SPACE42) is a UAE-based AI-powered SpaceTech company that integrates satellite communications, geospatial analytics and artificial intelligence capabilities to enlighten the Earth from space. Formed in 2024 by the successful merger of Bayanat and Yahsat, Space42's global reach allows it to address the rapidly evolving needs of its customers in governments, enterprises, and communities. Space42 comprises two business units: Space Services and Smart Solutions. Space Services focuses on upstream satellite operations for both fixed and mobility satellite services. Smart Solutions integrates geospatial data acquisition and processing with AI to inform decision-making, enhance situational awareness, and improve operational efficiency. Major shareholders include G42, Mubadala, and IHC.

For more information, visit: www.space42.ai; follow us on X: @space42ai

About Viasat

Viasat is a global communications company that believes everyone and everything in the world can be connected. With offices in 24 countries around the world, our mission shapes how consumers, businesses, governments and militaries around the world communicate and connect. Viasat is developing the ultimate global communications network to power high-quality, reliable, secure, affordable, fast connections to positively impact people's lives anywhere they are, on the ground, in the air or at sea, while building a sustainable future in space. In May 2023, Viasat completed its acquisition of Inmarsat, combining the teams, technologies and resources of the two companies to create a new global communications partner. Learn more at www.viasat.com, the Viasat News Room or follow us on LinkedIn, X, Instagram, Facebook, Bluesky, Threads, and YouTube.

Copyright © 2026 Viasat, Inc. All rights reserved. Viasat, the Viasat logo and the Viasat Signal are registered trademarks in the U.S. and in other countries of Viasat, Inc. All other product or company names mentioned are used for identification purposes only and may be trademarks of their respective owners.

Legal Notice and Cautionary Statement regarding forward-looking information

This announcement may contain forward-looking statements based on current expectations and assumptions about future events. These statements, identified by terms such as "expect," "will," or similar, are subject to risks and uncertainties and may prove inaccurate. They reflect information available as of the date hereof, and the companies disclaim any obligation to update them. No assurance is given that any forward-looking statement will occur, and undue reliance should not be placed on them. This announcement does not constitute a financial promotion or an offer to buy or sell securities in any jurisdiction.

Contact: [email protected]

ZURICH, SWITZERLAND – March 2, 2026 -- VERAXA Biotech AG (“VERAXA”), an emerging leader in designing novel cancer therapies, today announced that its shareholders approved the merger between VERAXA and Veraxa Biotech Holding AG and the issuance of new shares of the combined company at the Extraordinary General Meeting (“EGM”) on February 27, 2026. Both resolutions are prerequisites for the closing of the proposed business combination (the “Business Combination”) among VERAXA, Veraxa Biotech Holding AG and Voyager Acquisition Corp. (NASDAQ: VACH, “Voyager”), a special purpose acquisition company sponsored by Cantor Fitzgerald & Co., Voyager Acquisition Sponsor Holdco LLC, and Odeon Capital Group LLC.

The merger will be carried out by means of an absorption merger. Veraxa Biotech Holding AG, as the acquiring company, will take over VERAXA as the transferring company and simultaneously change its name to Veraxa Biotech AG. VERAXA will continue to operate under its existing management team led by Chief Executive Officer, Christoph Antz. Additionally, the EGM approved an ordinary capital increase of a maximum of CHF 223,400.00 and offering the corresponding number of shares to the shareholders of Voyager in connection with the business combination.

“We appreciate our shareholders’ support and their approval to take the next steps in our business combination process with Voyager”, said Christoph Antz, Ph.D., Chief Executive Officer of VERAXA. “VERAXA is well-positioned to generate significant long-term value by addressing the growing need for safer and more effective cancer therapies with a focus on antibody-drug conjugates and bispecific
T cell engagers. We look forward to continuing our path to becoming a leading innovator in cancer medicine.”

Subject to the approval of Voyager’s shareholders, VERAXA and Voyager will commence final procedures towards closing the Business Combination and the expected trading of shares of the combined company on NASDAQ under the symbol “VRXA”. The resolutions of the EGM are subject to the condition of the approval of the Business Combination by Voyager’s shareholders.

About the Business Combination

On April 22, 2025, VERAXA entered into a definitive business combination agreement (the "Business Combination Agreement") with Voyager Acquisition Corp., a Cayman Islands exempted company and special purpose acquisition company targeting the healthcare sector (NASDAQ: VACH, "Voyager"). Upon closing of the Business Combination, the combined company is expected to become a publicly traded company listed on NASDAQ trading under the symbol “VRXA”.

The description of the Business Combination contained herein is only a high-level summary and is qualified in its entirety by reference to the underlying documents filed with the Securities and Exchange Commission (the “SEC”). A more detailed description of the terms of the transaction has been provided in a proxy statement/prospectus filed with the SEC by Voyager on February 19, 2026.

Note to Shareholders of VERAXA Biotech AG

In preparation for the registration of shares and subsequent share trading, we ask all shareholders of VERAXA Biotech AG to do the following:

To prepare your registration within the US share register, please send us your current email address to [email protected] by March 6, 2026.Please ensure that your shares are or will be registered by your bank with the Computershare share register.To avoid short selling, please ensure that your shares are not used for lending by your bank. About VERAXA Biotech AG

At VERAXA, we are building a premier engine for the discovery and development of next-generation antibody-based therapeutics, including bispecific ADCs, bispecific T cell engagers and other innovative formats. Powered by a suite of transformative technologies and guided by rigorous quality-by-design principles, we are rapidly advancing our pipeline of ADCs and proprietary BiTAC formats into clinical development and beyond. VERAXA was founded on scientific breakthroughs made at the European Molecular Biology Laboratory, a world-renowned institution known for pioneering life science research and cutting-edge technology.

For regular updates about VERAXA Biotech, visit www.veraxa.com. You can also follow us on LinkedIn.

About Voyager Acquisition Corp.

Voyager is a special purpose acquisition company with a bold mission: to revolutionize the healthcare sector through a merger, stock purchase, or business combination. Our team of experienced executives includes unparalleled expertise in investing, operations, and medical innovation, supported by a vast network of connections. With these strengths, we not only seek to drive success but commit to scaling companies to unprecedented heights in the healthcare industry. For more information, please visit https://www.voyageracq.com.

Participants In the Solicitation

Voyager, VERAXA, and their respective directors, executive officers, other members of management, and employees may be deemed participants in the solicitation of proxies from Voyager’s stockholders with respect to the Business Combination. Investors and security holders may obtain more detailed information regarding the names and interests in the Business Combination of Voyager’s directors and officers in Voyager’s filings with the SEC, including the preliminary proxy statement/prospectus, the definitive proxy statement/prospectus, amendments and supplements thereto, and other documents filed with the SEC. Such information with respect to VERAXA’s directors and executive officers is also included in the proxy statement/prospectus. You may obtain free copies of these documents as described below under the heading "Additional Information and Where to Find It".

Non-Solicitation

This press release is not a proxy statement or solicitation of a proxy, consent or authorization with respect to any securities or in respect of the potential transaction and shall not constitute an offer to sell or a solicitation of an offer to buy the securities of Voyager or VERAXA, nor shall there be any sale of any such securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction. No offer of securities shall be made except by means of a prospectus meeting the requirements of the Securities Act of 1933, as amended.

Forward-Looking Statements

This press release includes certain statements that may be considered forward-looking statements within the meaning of the federal securities laws. Forward-looking statements include, without limitation, statements about future events or Voyager’s or VERAXA’s future financial or operating performance. For example, statements regarding VERAXA’s anticipated growth and the anticipated growth and other metrics, statements regarding the benefits of the Business Combination, and the anticipated timing of the completion of the Business Combination are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “may,” “should,” “could,” “might,” “plan,” “possible,” “project,” “strive,” “budget,” “forecast,” “expect,” “intend,” “will,” “estimate,” “anticipate,” “believe,” “predict,” “potential” or “continue,” or the negatives of these terms or variations of them or similar terminology.

These forward-looking statements regarding future events and the future results of Voyager and VERAXA are based on current expectations, estimates, forecasts, and projections about the industry in which VERAXA operates, as well as the beliefs and assumptions of Voyager’s management and VERAXA’s management. These forward-looking statements are only predictions and are subject to, without limitation, (i) known and unknown risks, including the risks and uncertainties indicated from time to time in the final prospectus of Voyager relating to its initial public offering filed with the SEC, and in the proxy statement/prospectus filed by Voyager and VERAXA on February 19, 2026, including those under “Risk Factors” therein, and other documents filed or to be filed with the SEC by Voyager; (ii) uncertainties; (iii) assumptions; and (iv) other factors beyond Voyager’s or VERAXA’s control that are difficult to predict because they relate to events and depend on circumstances that will occur in the future. They are neither statements of historical fact nor promises or guarantees of future performance. Therefore, VERAXA’s actual results may differ materially and adversely from those expressed or implied in any forward-looking statements and Voyager and VERAXA therefore caution against relying on any of these forward-looking statements.

These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by Voyager and its management and VERAXA and its management, as the case may be, are inherently uncertain and are inherently subject to risks, variability and contingencies, many of which are beyond Voyager’s or VERAXA’s control. Factors that may cause actual results to differ materially from current expectations include, but are not limited to: (i) the occurrence of any event, change or other circumstances that could give rise to the termination of the Business Combination Agreement and any subsequent definitive agreements with respect to the Business Combination; (ii) the outcome of any legal proceedings that may be instituted against Voyager, VERAXA, or others following the announcement of the Business Combination and any definitive agreements with respect thereto; (iii) the inability to complete the Business Combination due to the failure to obtain consents and approvals of the shareholders of Voyager, to obtain financing to complete the Business Combination or to satisfy other conditions to closing, or delays in obtaining, adverse conditions contained in, or the inability to obtain necessary regulatory approvals required to complete the transactions contemplated by the Business Combination Agreement; (iv) the failure to realize estimated shareholder redemptions, purchase price and other adjustments; and (v) other risks and uncertainties set forth in the filings by Voyager with the SEC. There may be additional risks that neither Voyager nor VERAXA presently know or that Voyager and VERAXA currently believe are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. Any forward-looking statements made by or on behalf of Voyager or VERAXA speak only as of the date they are made. None of Voyager or VERAXA undertakes any obligation to update any forward-looking statements to reflect any changes in their respective expectations with regard thereto or any changes in events, conditions or circumstances on which any such statement is based.

Additional Information and Where to Find It

In connection with the Business Combination Agreement, Voyager and VERAXA have filed a proxy statement/prospectus of Voyager, and will file other documents regarding the proposed transaction with the SEC. This communication is not intended to be, and is not, a substitute for the proxy statement/prospectus or any other document that Voyager has filed or may file with the SEC in connection with the proposed transaction. The definitive proxy statement and other relevant materials for the proposed transaction have been mailed or made available to stockholders of Voyager as of a record date to be established for voting on the proposed transaction.

Before making any voting or investment decision, investors and stockholders of Voyager are urged to carefully read the entire registration statement, the proxy statement/prospectus, and any other relevant documents filed with the SEC, as well as any amendments or supplements to these documents, and the documents incorporated by reference therein, because they will contain important information about Voyager, VERAXA, and the proposed transaction. Voyager’s investors and stockholders and other interested persons can also obtain copies of the registration statement, the preliminary proxy statement/prospectus, the definitive proxy statement/prospectus, other documents filed with the SEC that will be incorporated by reference therein, and all other relevant documents filed with the SEC by Voyager and/or VERAXA in connection with the transaction, without charge, once available, at the SEC’s website at www.sec.gov, or by directing a request to Voyager at the address set forth below.

Contact

20260302_PR_Veraxa_EGM_Approval_FINAL_docx

Sanofi’s rilzabrutinib earns orphan drug designation in Japan for IgG4-related disease

Designation based on positive data from a phase 2 study of rilzabrutinib in IgG4-RDThird global orphan drug designation for rilzabrutinib in IgG4-RD, underpinning Sanofi’s commitment to rare immune-mediated diseases Paris, March 2, 2026 – The Ministry of Health, Labour and Welfare (MHLW) in Japan has granted orphan drug designation to rilzabrutinib, a novel, oral, reversible covalent Bruton’s tyrosine kinase (BTK) inhibitor, for IgG4-related disease (IgG4-RD). There is still unmet medical need and limited treatment options in Japan for IgG4-RD, a rare, progressive, immune-mediated chronic condition in which the immune system attacks various tissues and organs leading to serious damage. The MHLW grants orphan designation to medicines that address rare diseases or conditions with unmet medical needs.

Rilzabrutinib for the treatment of IgG4-RD was evaluated in a phase 2 study (clinical study identifier: NCT04520451) and results were presented at the European Alliance of Associations for Rheumatology 2025 congress. In IgG4-RD patients, treatment with rilzabrutinib for 52 weeks led to reduction in disease flares and other disease markers and minimized the need for treatment with glucocorticoids. The safety profile of rilzabrutinib in the study was consistent with previous studies in other indications, with no new safety signals observed. Treatment-emergent adverse events reported by >10% of patients include diarrhea, COVID-19, dizziness, dry mouth and nausea. Currently, rilzabrutinib in IgG4-RD is being evaluated in the RILIEF phase 3 study (clinical study identifier: NCT07190196).

Rilzabrutinib is being studied across multiple rare immune-mediated diseases. In 2025, it received approval for immune thrombocytopenia (ITP) in the US, the EU, and the UAE. Additionally, rilzabrutinib is currently under regulatory review for ITP in Japan. Rilzabrutinib has received several expedited designations from global regulatory authorities for ITP, IgG4-RD, warm autoimmune hemolytic anemia (wAIHA), and sickle cell disease (SCD). Other than the approved ITP indications in the US, EU, and UAE, these uses of rilzabrutinib are investigational and have not been evaluated by any regulatory authority.

About rilzabrutinib
Rilzabrutinib, Wayrilz where approved, is a novel, oral, reversible covalent BTK inhibitor that has the potential to be an effective new medicine for several rare immune-mediated or inflammatory diseases by working to restore immune balance via multi-immune modulation. BTK, expressed in B cells, macrophages, and other innate immune cells, plays a critical role in multiple immune-mediated disease processes and inflammatory pathways. With the application of the TAILORED COVALENCY® technology, rilzabrutinib can selectively inhibit the BTK target. Rilzabrutinib is now approved for the treatment of immune thrombocytopenia (ITP) in the US, the EU, and the UAE. Regulatory review for use in ITP is currently ongoing in Japan.

About IgG4-RD
IgG4-RD is a progressive, relapsing, chronic immune-mediated rare disease, which can manifest in almost every organ and can lead to organ damage and irreversible dysfunction with a sometimes fatal outcome. People with IgG4-RD experience flare-ups of the condition characterized by periods of exacerbated symptoms. Due to its rarity and challenges with diagnosis, the global prevalence of IgG4-RD is unknown.

About Sanofi
Sanofi is an R&D driven, AI-powered biopharma company committed to improving people’s lives and delivering compelling growth. We apply our deep understanding of the immune system to invent medicines and vaccines that treat and protect millions of people around the world, with an innovative pipeline that could benefit millions more. Our team is guided by one purpose: we chase the miracles of science to improve people’s lives; this inspires us to drive progress and deliver positive impact for our people and the communities we serve, by addressing the most urgent healthcare, environmental, and societal challenges of our time.
Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY

Media Relations
Sandrine Guendoul | +33 6 25 09 14 25 | [email protected]
Evan Berland | +1 215 432 0234 | [email protected]
Léo Le Bourhis | +33 6 75 06 43 81 | [email protected]
Victor Rouault | +1 617 356 4751 | [email protected]
Timothy Gilbert | +1 516 521 2929 | [email protected]
Léa Ubaldi | +33 6 30 19 66 46 | [email protected]
Ekaterina Pesheva | +1 410 926 6780 | [email protected]

Investor Relations
Thomas Kudsk Larsen | +44 7545 513 693 | [email protected]
Alizé Kaisserian | +33 6 47 04 12 11 | [email protected]
Keita Browne | +1 781 249 1766 | [email protected]
Nathalie Pham | +33 7 85 93 30 17 | [email protected]
Nina Goworek | +1 908 569 7086 | [email protected]
Thibaud Châtelet | +33 6 80 80 89 90 | [email protected]
Yun Li | +33 6 84 00 90 72 | [email protected]

Sanofi forward-looking statements
This press release contains forward-looking statements within the meaning of applicable securities laws, including the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions regarding the marketing and other potential of the product; regarding potential future events and revenues from the product. Words such as “expect,” “anticipate,” “believe,” “intend,” “estimate,” “plan,” “can,” “contemplate,” “could,” “is designed to,” “may,” “might,” “potential,” “objective,” "attempt," “target,” “project,” "strategy," "strive," "desire," “predict,” “forecast,” “ambition,” “guideline,” "seek," “should,” “will,” "goal," or the negative of these and similar expressions are intended to identify forward-looking statements. Although Sanofi’s management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks, uncertainties and assumptions include among other things, unexpected regulatory actions or delays, or government regulation generally, that could affect the availability or commercial potential of the product, the fact that product may not be commercially successful; authorities’ decisions regarding whether and when to approve a product candidate; political pressure in the United States to mandate lower drug prices including “most favored nation” pricing for State Medicaid programs; the uncertainties inherent in research and development, including future clinical data and analysis of existing clinical data relating to the product, including post marketing, unexpected safety, quality or manufacturing issues; competition in general; risks associated with intellectual property and any related pending or future litigation and the ultimate outcome of such litigation, and volatile economic and market conditions, and the impact that global crises may have on us, our customers, suppliers, vendors, and other business partners, and the financial condition of any one of them, as well as on our employees and on the global economy as a whole. The risks and uncertainties also include the uncertainties discussed or identified in the public filings with the SEC and the French Markets Authority (AMF) made by Sanofi, including those listed under “Risk Factors” and “Cautionary Statement Regarding Forward-Looking Statements” in Sanofi’s annual report on Form 20-F for the year ended December 31, 2025 or contained in our periodic reports on Form 6-K. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements. In light of these risks, uncertainties and assumptions, you should not place undue reliance on any forward-looking statements contained herein.

All trademarks mentioned in this press release are the property of the Sanofi group.

Press_Release

FENhance 1 met its primary endpoint, showing investigational fenebrutinib significantly reduced relapses by 51% compared to teriflunomide in relapsing multiple sclerosis (RMS), consistent with FENhance 2 results showing 59% reductionFENhance 1 is the final study readout of the fenebrutinib pivotal clinical development programme in MS, following positive results for FENhance 2 in RMS and for FENtrepid in primary progressive multiple sclerosis (PPMS)Fenebrutinib has the potential to become the first and only high-efficacy oral, brain-penetrant treatment for both RMS and PPMS, showing a profound benefit on relapsing and progressive disease biologyTotality of data from all three Phase III fenebrutinib studies will be submitted to regulatory authorities Basel, 02 March 2026 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the pivotal Phase III study (FENhance 1) of fenebrutinib in RMS met its primary endpoint, showing clinically meaningful and statistically significant results. The study demonstrated that fenebrutinib, an investigational Bruton’s tyrosine kinase (BTK) inhibitor, markedly reduced the annualised relapse rate (ARR) by 51% compared to teriflunomide over a period of at least 96 weeks of treatment, consistent with FENhance 2 results showing a 59% reduction in ARR. Together, these results equate to approximately one relapse every 17 years. Secondary endpoints in both RMS studies show statistically significant and clinically meaningful reductions in brain lesions. Additionally, all progression endpoints show favorable trends for fenebrutinib.

Full data from the FENhance 1 and 2 studies will be shared at the American Academy of Neurology (AAN) Annual Meeting 2026 and submitted to regulatory authorities together with data from the FENtrepid study.

“These pivotal results, together with the earlier data,  provide convincing evidence that fenebrutinib can become the first high-efficacy oral treatment for RMS and PPMS,” said Levi Garraway, M.D., Ph.D., Roche’s Chief Medical Officer and Head of Global Product Development. “Building on a decade of transforming MS treatment, we are committed to advancing innovation to one day allow people with MS to live a life without disability.”

The positive FENhance 1 study follows positive results for FENhance 2 in RMS and for FENtrepid in PPMS, which were both announced in November. The collective positive results across all three pivotal studies demonstrate that fenebrutinib consistently shows a profound benefit on relapsing and progressive disease biology.

In both RMS studies, liver transaminase elevations were comparable with teriflunomide. In the FENhance 1 study, there was one Hy’s Law case in the fenebrutinib arm and one in the teriflunomide arm. Both cases were asymptomatic and resolved after study drug discontinuation. There were no additional Hy's Law cases across all of the fenebrutinib clinical development programme in MS or in other autoimmune diseases.

In the FENhance 1 and 2 studies in RMS, 1 fatal case was reported in the teriflunomide arm and 8 fatal cases with various causes and at different points in treatment in the fenebrutinib arms. Further analyses are ongoing to better understand these findings.

Fenebrutinib targets cells in the immune system known as B cells and microglia. Targeting B cells helps control the acute inflammation that causes relapses, while targeting microglia inside the brain addresses the chronic damage that is thought to drive long-term disability progression. Fenebrutinib, a non-covalent BTK inhibitor, is designed to have high potency, selectivity and reversibility. This design allows it to act throughout the body, and also to cross the blood-brain barrier into the central nervous system (CNS) targeting chronic inflammation.

About the FENhance 1 and 2 studies
FENhance 1 and 2 are two Phase III multicentre, randomised, double-blind, double-dummy, parallel-group studies to evaluate the efficacy and safety of investigational fenebrutinib compared with teriflunomide in a total of 1,497 adult patients with RMS. Eligible participants were randomised 1:1 to receive treatment with either oral fenebrutinib twice a day (and placebo matched to oral teriflunomide once a day) or oral teriflunomide once a day (and placebo matched to oral fenebrutinib twice a day) for at least 96 weeks.

The primary endpoint is annualised relapse rate (ARR). Secondary endpoints include total number of T1-gadolinium-enhancing MRI lesions, total number of new and/or enlarging T2-weighted MRI lesions, time to onset of 12-week composite confirmed disability progression (cCDP12) and 24-week cCDP (cCDP24). cCDP incorporates three measures of disability – total functional disability measured by confirmed disability progression (CDP) based on the Expanded Disability Status Scale (EDSS), walking speed measured by the timed 25-foot walk (T25FW) and upper limb function measured by the nine-hole peg test (9HPT).

Following the double-blind treatment period, patients have the option to enter an open-label extension (OLE) phase, in which all patients receive treatment with fenebrutinib. 

About fenebrutinib
Fenebrutinib is an investigational oral, central nervous system (CNS)-penetrant, reversible and non-covalent Bruton’s tyrosine kinase (BTK) inhibitor with an optimised pharmacokinetics (PK) profile. Fenebrutinib can act throughout the body and also cross the blood-brain barrier into the CNS to target chronic inflammation. It is uniquely designed to target relapsing and progressive biology by inhibiting cells in the immune system known as B cells and microglia.  Targeting B cells helps control the acute inflammation that causes relapses, while targeting microglia inside the brain addresses the chronic damage that is thought to drive long-term disability progression.

Fenebrutinib is designed to have high potency and reversibility, with a selectivity for BTK 130 times greater than other kinases. This high selectivity highlights fenebrutinib's potential to bind to its intended target without interfering with other kinases. While most current BTK inhibitors are covalent and irreversible, meaning they form a permanent chemical bond with the enzyme, fenebrutinib is non-covalent and reversible, meaning it binds and then eventually releases the enzyme. These design features may help limit off-target effects.

The fenebrutinib Phase III programme includes two similarly designed trials in relapsing multiple sclerosis (RMS) (FENhance 1 and 2) with active comparator teriflunomide and the only trial in primary progressive multiple sclerosis (PPMS) (FENtrepid) in which a BTK inhibitor is being evaluated against OCREVUS.

To date, more than 2,700 patients and healthy volunteers have been treated with fenebrutinib in Phase I, II and III clinical programmes across multiple diseases, including multiple sclerosis and other autoimmune disorders.

About multiple sclerosis
Multiple sclerosis is a chronic disease that affects more than 2.9 million people worldwide. People with all forms of multiple sclerosis experience disease progression from the beginning of their disease. Therefore, an important goal of treating multiple sclerosis is to slow, stop and ideally prevent progression as early as possible.

Approximately 85% of people with multiple sclerosis are initially diagnosed with relapsing-remitting multiple sclerosis (RRMS). Relapsing forms of the disease (RMS) include RRMS and active secondary progressive MS, and people with RMS experience relapses and worsening disability over time. Primary progressive multiple sclerosis (PPMS) is a debilitating form of the disease marked by steadily worsening symptoms but typically without distinct relapses or periods of remission. Approximately 15% of people with multiple sclerosis are diagnosed with the primary progressive form of the disease. Until the FDA approval of OCREVUS®, there had been no FDA-approved treatments for PPMS and OCREVUS is still the only approved treatment for PPMS.

Despite the availability of CD20s, 30% of patients remain on low-efficacy oral therapy today. Slowing or stopping progression while simultaneously stopping relapses remains a high unmet need in MS.

About Roche in Neurology
Neurology is a major focus of research and development at Roche. Our goal is to pursue groundbreaking science to develop new treatments that help improve the lives of people with chronic and potentially devastating diseases.

Roche is investigating more than a dozen medicines for neurological disorders, including multiple sclerosis, spinal muscular atrophy, neuromyelitis optica spectrum disorder, Alzheimer’s disease, Huntington’s disease, Parkinson’s disease and Duchenne muscular dystrophy. Together with our partners, we are committed to pushing the boundaries of scientific understanding to solve some of the most difficult challenges in neuroscience today.

About Roche
Founded in 1896 in Basel, Switzerland, as one of the first industrial manufacturers of branded medicines, Roche has grown into the world’s largest biotechnology company and the global leader in in-vitro diagnostics. The company pursues scientific excellence to discover and develop medicines and diagnostics for improving and saving the lives of people around the world. We are a pioneer in personalised healthcare and want to further transform how healthcare is delivered to have an even greater impact. To provide the best care for each person we partner with many stakeholders and combine our strengths in Diagnostics and Pharma with data insights from the clinical practice.

For over 125 years, sustainability has been an integral part of Roche’s business. As a science-driven company, our greatest contribution to society is developing innovative medicines and diagnostics that help people live healthier lives. Roche is committed to the Science Based Targets initiative and the Sustainable Markets Initiative to achieve net zero by 2045. 

Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan.

For more information, please visit www.roche.com.

All trademarks used or mentioned in this release are protected by law.
 

Roche Global Media Relations
Phone: +41 61 688 8888 / e-mail: [email protected]

Hans Trees, PhD
Phone: +41 79 407 72 58Nathalie Altermatt
Phone: +41 79 771 05 25Lorena Corfas
Phone: +41 79 568 24 95Simon Goldsborough
Phone: +44 797 32 72 915Karsten Kleine
Phone: +41 79 461 86 83Kirti Pandey
Phone: +49 172 6367262Yvette Petillon
Phone: +41 79 961 92 50Dr Rebekka Schnell
Phone: +41 79 205 27 03
Roche Investor Relations

Dr Bruno Eschli
Phone: +41 61 68-75284
e-mail: [email protected] Sabine Borngräber
Phone: +41 61 68-88027
e-mail: [email protected] Birgit Masjost
Phone: +41 61 68-84814
e-mail: [email protected]  Investor Relations North America

Loren Kalm
Phone: +1 650 225 3217
e-mail: [email protected]
  Media Investor Release fenebrutinib FENhance 1 study English